Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer.

This article discusses a prospective cohort study that examined the use of circulating tumor DNA (ctDNA) as a biomarker to predict failure patterns and the efficacy of consolidation immunotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) who received chemoradiotherapy (CRT). The study found that dynamic ctDNA levels could predict failure patterns and identify patients who may benefit from consolidation immunotherapy. Patients with decreased ctDNA levels after CRT had a higher risk of distant metastasis but showed more benefit from immunotherapy, while patients with increased ctDNA levels had a higher risk of both local-regional and distant failure and also showed benefit from immunotherapy. The study suggests that ctDNA testing could be used to personalize treatment decisions and improve outcomes for LA-NSCLC patients. [Extracted from the article]